Frontiers in Cardiovascular Medicine

FEBRUARY 20, 2024

We investigated whether treatment with LDE-paclitaxel changes plaque progression by coronary CT angiography and is safe in patients with chronic coronary artery disease. Clinical and laboratory safety evaluations were made at baseline and every 3 weeks until the end of the study.

Coronary Artery Disease 59

Coronary Artery Disease Laboratory Plaque Biomarkers 59

Frontiers in Cardiovascular Medicine

JULY 5, 2024

Coronary artery disease is caused by the buildup of atherosclerotic plaque in the coronary arteries, affecting the blood supply to the heart, one of the leading causes of death around the world.

Laboratory 52

Laboratory Coronary Artery Disease Interventional Cardiology Plaque 52

Circulation

JANUARY 15, 2024

Nevertheless, the relationship between CAC and the susceptibility of a plaque to provoke a thrombotic event remains incompletely understood. Nevertheless, the relationship between CAC and the susceptibility of a plaque to provoke a thrombotic event remains incompletely understood.

Coronary Artery Disease 45

Coronary Artery Disease Atherosclerosis Laboratory Plaque 45

Circulation: Cardiovascular Imaging

FEBRUARY 19, 2024

BACKGROUND:It is not known whether there is a sex difference in the association between perivascular inflammation and plaque vulnerability. All images were analyzed at a core laboratory. plaques per patient) and 784 lesions in 327 men (2.4 plaques per patient). plaques per patient) and 784 lesions in 327 men (2.4

Plaque 73

Plaque Coronary Artery Disease Laboratory Cardiovascular Imaging 73